Kidney Cancer

Clinical Trials


DISSRM (Delayed Intervention and Active Surveillance for Small Renal Masses) Registry

Eligibility:
Ages Eligible for Study: 18 Years to 100 Years (Adult, Senior)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: Yes
Sampling Method: Non-Probability Sample

Study Population
All adult patients (18-100) presenting with a clinically localized, solid renal mass (cT1a, <=4cm).

Criteria

Inclusion Criteria:
•Must have a solid, enhancing renal mass ≤4cm at its greatest dimension found on incidental scanning in the last 6 months.
•Age ≥ 18 and able to read, understand and sign informed consent.
•Must be willing to adhere to the treatment algorithm and time constraints therein.

Exclusion Criteria:
•Cannot have suspicion of metastases to the kidney if any other malignancy diagnosed within two years of study entry.


Overview:
This study is open to any patient with a small renal mass (less than 4cm) suspicious for kidney cancer. The registry catalogs outcomes for patients who choose either active surveillance (http://urology.jhu.edu/kidney_cancer/kidney_cancer_AS_Registry.php) or surgical intervention. The DISSRM Registry was opened in 2009 and is the world's largest, ongoing active surveillance program for kidney tumors.

PI: Phillip M. Pierorazio, M.D.

Contact Name: Tina Driscoll
Email: twlajni1@jhmi.edu


Neoadjuvant Nivolumab for Locally Advanced Kidney Cancer

Eligibility:
This study is for patients with large or locally advanced kidney tumors. Nivolumab is among a new class of immunotherapy medications that have shown incredible promise for patients with metastatic kidney cancer. Investigators at Johns Hopkins are offering the first trial of its kind in the world, offering nivolumab prior to high-risk patients prior to surgery. Patients with large tumors (greater than 7cm), enlarged lymph nodes or tumors with vascular invasion are eligible for the study.

PI: Mohamad Allaf

Contact Name: Clinical Trials Office
Phone: 410-955-8804
Email: jhcccro@jhmi.edu


Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma

Eligibility:
Ages Eligible for Study: 18 Years to 100 Years (Adult, Senior)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:
•Clinically diagnosed or histologically proven stage II-IV renal cell carcinoma
•Completed staging evaluation with computed tomography (CT) or magnetic resonance imaging (MRI) of the chest, abdomen and pelvis ≤90 days prior to study enrollment

Exclusion Criteria:
•History of other malignancy diagnosed within the last 3 years (with the exception of low risk prostate cancer, ductal carcinoma in situ of the breast, squamous cell carcinoma or basal cell carcinoma of the skin)
•Administered a radioisotope within 5 physical half-lives prior to study enrollment
•Pregnancy ((as determined in accordance with the policies of the positron emission tomography (PET) center))
•Intention to enroll in a blinded therapeutic clinical trial following Positron emission tomography-computed tomography (PET/CT)


Overview:
In this study the investigators aim to evaluate diagnostic utility of PSMA-targeted 18F-DCFPyL PET/CT in patients with renal cell carcinoma.

PI: Mohamad E. Allaf, M.D.

Contact Name: Michael A. Gorin, M.D.
Phone: 410-614-8151
Email: mgorin1@jhmi.edu

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved. Disclaimer
Email: webmaster@urology.jhu.edu | 600 North Wolfe Street, Baltimore, Maryland 21287

urology second opinion urology second opinion